{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:42:54Z","timestamp":1790174574986,"version":"4.1.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T00:00:00Z","timestamp":1611705600000},"content-version":"vor","delay-in-days":593,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T00:00:00Z","timestamp":1560470400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T00:00:00Z","timestamp":1560470400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100004622","name":"Dutch Cancer Society","doi-asserted-by":"publisher","award":["UU2014-6617"],"award-info":[{"award-number":["UU2014-6617"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000654","name":"Marie Curie Network Ploidynet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000654","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011102","name":"European Union Seventh Framework Programme","doi-asserted-by":"publisher","award":["FP7\/2007-2013"],"award-info":[{"award-number":["FP7\/2007-2013"]}],"id":[{"id":"10.13039\/100011102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011102","name":"European Union Seventh Framework Programme","doi-asserted-by":"publisher","award":["607722"],"award-info":[{"award-number":["607722"]}],"id":[{"id":"10.13039\/100011102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["UU2014\u20136617"],"award-info":[{"award-number":["UU2014\u20136617"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011102","name":"Seventh Framework Programme","doi-asserted-by":"publisher","award":["FP7\/2007\u20102013"],"award-info":[{"award-number":["FP7\/2007\u20102013"]}],"id":[{"id":"10.13039\/100011102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011102","name":"Seventh Framework Programme","doi-asserted-by":"publisher","award":["607722"],"award-info":[{"award-number":["607722"]}],"id":[{"id":"10.13039\/100011102","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Patients with peritoneal metastases from colorectal cancer have a poor prognosis. If the intraperitoneal tumour load is limited, patients may be eligible for cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). This treatment has improved overall survival, but recurrence rates are high. The aim of this study was to create a preclinical platform for the development of more effective intraperitoneal chemotherapy strategies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Using organoid technology, five tumour cultures were generated from malignant ascites and resected peritoneal metastases. These were used in an in vitro HIPEC model to assess sensitivity to mitomycin C (MMC) and oxaliplatin, the drugs used most commonly in HIPEC. The model was also used to test a rational combination treatment involving MMC and inhibitors of the checkpoint kinase ATR.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>MMC was more effective in eliminating peritoneal metastasis-derived organoids than oxaliplatin at clinically relevant concentrations. However, the drug concentrations required to eliminate 50 per cent of the tumour cells (IC50) were higher than the median clinical dose in two of five organoid lines for MMC, and all five lines for oxaliplatin, indicating a general resistance to monotherapy. ATR inhibition increased the sensitivity of all peritoneal metastasis-derived organoids to MMC, as the IC50 decreased 2\u00b76\u201312\u00b74-fold to well below concentrations commonly attained in clinical practice. Live-cell imaging and flow cytometric analysis showed that ATR inhibition did not release cells from MMC-induced cell cycle arrest, but caused increased replication stress and accelerated cell death.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Peritoneal metastasis-derived organoids can be used to evaluate existing HIPEC regimens on an individual-patient level and for development of more effective treatment strategies. Surgical relevanceCytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC) has improved prognosis of patients with peritoneal metastases from colorectal cancer, but disease recurrence is common. More effective and personalized HIPEC is urgently needed. Organoid technology is frequently used for drug screens, as patient-derived organoids can accurately predict clinical therapeutic response in vitro.A panel of organoids was established from peritoneal metastases from colorectal cancer and used to develop a model for testing HIPEC regimens in vitro. Patient-derived organoids differed in sensitivity to commonly used chemotherapeutics, in line with variable clinical outcomes following cytoreductive surgery\u2013HIPEC. Combining MMC with an ATR inhibitor improved the efficacy of MMC.Peritoneal metastasis-derived organoids can be used as a platform to test novel (combination) strategies that increase HIPEC efficacy. In the future, organoids could be used to select patent-tailored HIPEC regimens.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/bjs.11206","type":"journal-article","created":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T07:41:53Z","timestamp":1560498113000},"page":"1404-1414","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":96,"title":["Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy"],"prefix":"10.1093","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8199-0226","authenticated-orcid":false,"given":"I","family":"Ubink","sequence":"first","affiliation":[{"name":"Department of Surgical Oncology, UMC Utrecht Cancer Centre , Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A C F","family":"Bolhaqueiro","sequence":"additional","affiliation":[{"name":"Oncode Institute, Hubrecht Institute \u2013 Royal Academy of Arts and Sciences and University Medical Centre Utrecht , Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S G","family":"Elias","sequence":"additional","affiliation":[{"name":"Julius Centre for Health Sciences and Primary Care , Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D A E","family":"Raats","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, UMC Utrecht Cancer Centre , Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Constantinides","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, UMC Utrecht Cancer Centre , Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N A","family":"Peters","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, UMC Utrecht Cancer Centre , Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E C E","family":"Wassenaar","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, UMC Utrecht Cancer Centre , Utrecht, the Netherlands"},{"name":"Department of Surgery, St Antonius Hospital , Nieuwegein, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I H J T","family":"de Hingh","sequence":"additional","affiliation":[{"name":"Department of Surgery, Catharina Hospital , Eindhoven, the Netherlands"},{"name":"GROW \u2013 School for Oncology and Developmental Biology, Maastricht University , Maastricht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K P","family":"Rovers","sequence":"additional","affiliation":[{"name":"Department of Surgery, Catharina Hospital , Eindhoven, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W M U","family":"van Grevenstein","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, UMC Utrecht Cancer Centre , Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M M","family":"Lacl\u00e9","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Medical Centre Utrecht , Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G J P L","family":"Kops","sequence":"additional","affiliation":[{"name":"Oncode Institute, Hubrecht Institute \u2013 Royal Academy of Arts and Sciences and University Medical Centre Utrecht , Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I H M","family":"Borel Rinkes","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, UMC Utrecht Cancer Centre , Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Kranenburg","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, UMC Utrecht Cancer Centre , Utrecht, the Netherlands"},{"name":"Utrecht Platform for Organoid Technology, Utrecht University , Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,6,14]]},"reference":[{"key":"2022100812431114400_bjs11206-bib-0001","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/bjs.8679","article-title":"Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer","volume":"99","author":"Segelman","year":"2012","journal-title":"Br J Surg"},{"key":"2022100812431114400_bjs11206-bib-0002","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/01.sla.0000197702.46394.16","article-title":"Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies","volume":"243","author":"Koppe","year":"2006","journal-title":"Ann Surg"},{"key":"2022100812431114400_bjs11206-bib-0003","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1016\/j.ejso.2018.07.003","article-title":"The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI)","volume":"44","author":"Bushati","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"2022100812431114400_bjs11206-bib-0004","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1002\/cncr.25116","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis","volume":"116","author":"Franko","year":"2010","journal-title":"Cancer"},{"key":"2022100812431114400_bjs11206-bib-0005","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.2009.23.9285","article-title":"Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study","volume":"28","author":"Elias","year":"2010","journal-title":"J Clin Oncol"},{"key":"2022100812431114400_bjs11206-bib-0006","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1245\/s10434-008-9966-2","article-title":"8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer","volume":"15","author":"Verwaal","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"2022100812431114400_bjs11206-bib-0007","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ejso.2017.10.216","article-title":"Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC","volume":"44","author":"van Eden","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"2022100812431114400_bjs11206-bib-0008","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/jso.23728","article-title":"The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery","volume":"110","author":"Prada-Villaverde","year":"2014","journal-title":"J Surg Oncol"},{"key":"2022100812431114400_bjs11206-bib-0009","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ejso.2016.09.015","article-title":"Oxaliplatin versus Mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis","volume":"43","author":"Leung","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"2022100812431114400_bjs11206-bib-0010","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/jso.23546","article-title":"The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study","volume":"109","author":"Hompes","year":"2014","journal-title":"J Surg Oncol"},{"key":"2022100812431114400_bjs11206-bib-0011","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.1245\/s10434-013-3145-9","article-title":"Cytoreduction and HIPEC in The Netherlands: nationwide long-term outcome following the Dutch protocol","volume":"20","author":"Kuijpers","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"2022100812431114400_bjs11206-bib-0012","doi-asserted-by":"crossref","first-page":"LBA3503","DOI":"10.1200\/JCO.2018.36.18_suppl.LBA3503","article-title":"A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7","volume":"36","author":"Quenet","year":"2018","journal-title":"J Clin Oncol"},{"key":"2022100812431114400_bjs11206-bib-0013","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"N Engl J Med"},{"key":"2022100812431114400_bjs11206-bib-0014","doi-asserted-by":"crossref","first-page":"S873","DOI":"10.1245\/s10434-015-4679-9","article-title":"Mitomycin C pharmacokinetics as predictor of severe neutropenia in hyperthermic intraperitoneal therapy","volume":"22","author":"Kemmel","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"2022100812431114400_bjs11206-bib-0015","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41568-018-0034-3","article-title":"Targeting ATR in cancer","volume":"18","author":"Lecona","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"2022100812431114400_bjs11206-bib-0016","first-page":"169","article-title":"Structural and function modification of DNA by mitomycin C. Mechanism of the DNA sequence specificity of mitomycins","author":"Gargiulo","year":"1995","journal-title":"Nucleic Acids Symp Ser"},{"key":"2022100812431114400_bjs11206-bib-0017","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.molcel.2017.05.001","article-title":"Replication catastrophe: when a checkpoint fails because of exhaustion","volume":"66","author":"Toledo","year":"2017","journal-title":"Mol Cell"},{"key":"2022100812431114400_bjs11206-bib-0018","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.cell.2015.03.053","article-title":"Prospective derivation of a living organoid biobank of colorectal cancer patients","volume":"161","author":"van de Wetering","year":"2015","journal-title":"Cell"},{"key":"2022100812431114400_bjs11206-bib-0019","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1126\/science.aao2774","article-title":"Patient-derived organoids model treatment response of metastatic gastrointestinal cancers","volume":"359","author":"Vlachogiannis","year":"2018","journal-title":"Science"},{"key":"2022100812431114400_bjs11206-bib-0020","doi-asserted-by":"crossref","first-page":"e18489","DOI":"10.7554\/eLife.18489","article-title":"Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening","volume":"5","author":"Verissimo","year":"2016","journal-title":"Elife"},{"key":"2022100812431114400_bjs11206-bib-0021","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2165\/00003088-200443020-00005","article-title":"Population pharmacokinetics and pharmacodynamics of mitomycin during intraoperative hyperthermic intraperitoneal chemotherapy","volume":"43","author":"van Ruth","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"2022100812431114400_bjs11206-bib-0022","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ijpharm.2014.12.025","article-title":"Stability of oxaliplatin in chloride-containing carrier solutions used in hyperthermic intraperitoneal chemotherapy","volume":"479","author":"Mehta","year":"2015","journal-title":"Int J Pharm"},{"key":"2022100812431114400_bjs11206-bib-0023","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.cell.2013.10.043","article-title":"ATR prohibits replication catastrophe by preventing global exhaustion of RPA","volume":"155","author":"Toledo","year":"2013","journal-title":"Cell"},{"key":"2022100812431114400_bjs11206-bib-0024","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.semcdb.2018.04.005","article-title":"Replication protein A, the laxative that keeps DNA regular: the importance of RPA phosphorylation in maintaining genome stability","volume":"86","author":"Byrne","year":"2019","journal-title":"Semin Cell Dev Biol"},{"key":"2022100812431114400_bjs11206-bib-0025","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nchembio.573","article-title":"Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR","volume":"7","author":"Reaper","year":"2011","journal-title":"Nat Chem Biol"},{"key":"2022100812431114400_bjs11206-bib-0026","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3389\/fimmu.2018.00663","article-title":"Increased plasma levels of danger-associated molecular patterns are associated with immune suppression and postoperative infections in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"9","author":"Leijte","year":"2018","journal-title":"Front Immunol"},{"key":"2022100812431114400_bjs11206-bib-0027","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1002\/bjs.10788","article-title":"Histopathological and molecular classification of colorectal cancer and corresponding peritoneal metastases","volume":"105","author":"Ubink","year":"2018","journal-title":"Br J Surg"},{"key":"2022100812431114400_bjs11206-bib-0028","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41586-018-0024-3","article-title":"Intra-tumour diversification in colorectal cancer at the single-cell level","volume":"556","author":"Roerink","year":"2018","journal-title":"Nature"}],"container-title":["British Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbjs.11206","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bjs.11206","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bjs.11206","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/bjs\/article-pdf\/106\/10\/1404\/46376014\/bjs11206.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjs\/article-pdf\/106\/10\/1404\/46376014\/bjs11206.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T13:02:22Z","timestamp":1665234142000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjs\/article\/106\/10\/1404\/6120874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,14]]},"references-count":28,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,6,14]]},"published-print":{"date-parts":[[2019,8,15]]}},"URL":"https:\/\/doi.org\/10.1002\/bjs.11206","relation":{},"ISSN":["0007-1323","1365-2168"],"issn-type":[{"value":"0007-1323","type":"print"},{"value":"1365-2168","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,9]]},"published":{"date-parts":[[2019,6,14]]},"assertion":[{"value":"2019-01-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}